HR-4976 : Still Just a Bill


Opioid Review Modernization Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refer new drug applications for opioids (drugs with effects similar to opium, such as certain pain medications) to an advisory committee before approval, unless the FDA finds that such a referral is scientifically unnecessary and not in the interest of protecting and promoting public health and the FDA notifies Congress of its rationale.

The FDA must convene an advisory committee on labeling opioids for pediatric use before approving any such labeling.

As part of its evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, the FDA must develop recommendations regarding education programs for prescribers of opioids.

The FDA must finalize the draft guidance entitled "General Principals for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products."

Action Timeline

Action DateTypeTextSource
2016-05-12IntroReferralReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Senate
2016-05-11FloorMotion to reconsider laid on the table Agreed to without objection.House floor actions
2016-05-11FloorOn motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2254-2256)House floor actions
2016-05-11FloorDEBATE - The House proceeded with forty minutes of debate on H.R. 4976.House floor actions
2016-05-11FloorConsidered under suspension of the rules. (consideration: CR H2254-2256)House floor actions
2016-05-11FloorMr. Guthrie moved to suspend the rules and pass the bill.House floor actions
2016-05-10CalendarsPlaced on the Union Calendar, Calendar No. 431.House floor actions
2016-05-10CommitteeReported by the Committee on Energy and Commerce. H. Rept. 114-557.House floor actions
2016-04-27CommitteeOrdered to be Reported by Voice Vote.House committee actions
2016-04-27CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2016-04-26CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2016-04-25CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2016-04-20CommitteeForwarded by Subcommittee to Full Committee by Voice Vote .House committee actions
2016-04-20CommitteeSubcommittee Consideration and Mark-up Session Held.House committee actions
2016-04-18CommitteeReferred to the Subcommittee on Health.House committee actions
2016-04-18IntroReferralReferred to the House Committee on Energy and Commerce.House floor actions
2016-04-18IntroReferralIntroduced in HouseLibrary of Congress

Policy Area :

Health
Related Subjects
  • Administrative law and regulatory procedures
  • Advisory bodies
  • Child health
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Drug trafficking and controlled substances
  • Prescription drugs
Related Geographic Entities
Related Organizations
  • Department of Health and Human Services
  • Food and Drug Administration (FDA)

Related Bills

See Related Bills